Synopsis:- A healthcare stock is in focus after acquiring a leading brand to enter the ₹648 crore povidone iodine market. With 14 SKUs and strong distribution, the move boosts expansion. Operational performance improved, with operating profit rising from ₹69 crore to ₹83 crore and margins increasing to 24%.
The shares of this healthcare company will be in focus in tomorrow’s trading session after the company has acquired the Wokadine brand from Dr. Reddy’s Laboratories Ltd to enter the Rs 648 crore povidone iodine market.
With a market capitalization of Rs 9,517.43 crore, on Monday, the share of Corona Remedies Ltd closed at Rs 1,556.15 per share, decreased around 1.52 percent as compared to the previous closing price of Rs 1,580.15 apiece.
Povidone Iodine Market
According to the company filing, Corona Remedies Ltd has acquired the Wokadine brand from Dr. Reddy’s Laboratories Ltd, marking a strategic move to strengthen its specialty portfolio. As Wokadine ranks #2 in India’s povidone iodine market, the deal enhances its positioning while enabling deeper penetration into targeted therapeutic segments with wider accessibility.
Furthermore, the acquisition gives entry into the Rs 648 crore povidone iodine market and leverages a portfolio of 14 SKUs. Backed by a strong distribution network, the company aims to expand its reach across metro and rural markets. Fully funded through internal accruals, the move reflects confidence in long-term growth and operational scalability.
Commenting on the acquisition, Mr. Tejas Kothari, Vice President – Corporate Strategy & Business Development, said: “At CORONA Remedies, we continuously assess both organic and inorganic growth opportunities, focusing on strengthening our brands by leveraging CORONA’s extensive reach, strong trust among doctors and the medical fraternity, a pan-India distribution network, and a dedicated sales and marketing team. We believe this acquisition will enhance and strengthen our existing product portfolio. By building on our strong relationships with healthcare professionals, we aim to deepen market penetration and are confident in accelerating the growth of this brand.”
Financial & Other Highlights
The company reported mixed performance, with revenue rising 15% from Rs 298 crore to Rs 342 crore, indicating steady business growth. However, net profit declined 9% from Rs 45 crore to Rs 41 crore, suggesting margin pressure. Despite higher topline, increased costs or operational challenges appear to have impacted overall profitability during the quarter.
Between Dec 2024 and Dec 2025, operating profit increased from Rs 69 crore to Rs 83 crore, reflecting improved operational performance. Operating margin (OPM) also expanded from 23% to 24%, indicating better cost efficiency. Despite some quarterly fluctuations, the overall trend shows steady margin expansion and stronger profitability driven by controlled expenses and improved business mix.
The company is steadily diversifying its portfolio, with West contribution declining from 48.0% in FY23 to 46.3% in FY25, while South rises from 18.0% to 20.0% and East from 12.4% to 13.5%. Chronic therapies increased from 69.1% to 71.1%, reflecting a stronger focus on long-term, high-growth therapeutic segments.
Corona Remedies Ltd is a fast-growing pharmaceutical company focused on branded generics across key therapies such as women’s health, cardiology, and pain management. It emphasizes innovation, strong doctor engagement, and a wide distribution network, enabling deeper penetration across urban and rural markets while building a robust specialty-focused healthcare portfolio.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Healthcare stock to watch after acquiring Dr. Reddy’s brand to enter ₹648 Cr iodine market appeared first on Trade Brains.